Association of glycated hemoglobin A levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium.

Background: Biomarkers may contribute to improved cardiovascular risk estimation. Glycated hemoglobin A (HbA) is used to monitor the quality of diabetes treatment. Its strength of association with cardiovascular outcomes in the general population remains uncertain. This study aims to assess the association of HbA with cardiovascular outcomes in the general population.

Methods: Data from six prospective population-based cohort studies across Europe comprising 36,180 participants were analyzed. HbA was evaluated in conjunction with classical cardiovascular risk factors (CVRFs) for association with cardiovascular mortality, cardiovascular disease (CVD) incidence, and overall mortality in subjects without diabetes (N = 32,496) and with diabetes (N = 3684).

Results: Kaplan-Meier curves showed higher event rates with increasing HbA levels (log-rank-test: p < 0.001). Cox regression analysis revealed significant associations between HbA (in mmol/mol) in the total study population and the examined outcomes. Thus, a hazard ratio (HR) of 1.16 (95% confidence interval (CI) 1.02-1.31, p = 0.02) for cardiovascular mortality, 1.13 (95% CI 1.03-1.24, p = 0.01) for CVD incidence, and 1.09 (95% CI 1.02-1.17, p = 0.01) for overall mortality was observed per 10 mmol/mol increase in HbA. The association with CVD incidence and overall mortality was also observed in study participants without diabetes with increased HbA levels (HR 1.12; 95% CI 1.01-1.25, p = 0.04) and HR 1.10; 95% CI 1.01-1.20, p = 0.02) respectively. HbA cut-off values of 39.9 mmol/mol (5.8%), 36.6 mmol/mol (5.5%), and 38.8 mmol/mol (5.7%) for cardiovascular mortality, CVD incidence, and overall mortality, showed also an increased risk.

Conclusions: HbA is independently associated with cardiovascular mortality, overall mortality and cardiovascular disease in the general European population. A mostly monotonically increasing relationship was observed between HbA levels and outcomes. Elevated HbA levels were associated with cardiovascular disease incidence and overall mortality in participants without diabetes underlining the importance of HbA levels in the overall population.